The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EGFR-A763_Y764insFQEA: A unique exon 20 insertion mutation that displays sensitivity to all classes of approved lung cancer EGFR tyrosine kinase inhibitors.
 
Carol Gergis
No Relationships to Disclose
 
Deepa Rangachari
Consulting or Advisory Role - Advance Medical; DynaMed
 
Masanori Fujii
No Relationships to Disclose
 
Andreas Varkaris
No Relationships to Disclose
 
Paul A VanderLaan
Consulting or Advisory Role - Gala Therapeutics
 
Susumu Kobayashi
Honoraria - Boehringer Ingelheim; Chugai Pharma; Roche
Consulting or Advisory Role - Ono Pharmaceutical; Pfizer
Research Funding - Minapharma (Inst); Taiho Pharmaceutical (Inst)
 
Daniel Botelho Costa
Honoraria - Pfizer; Takeda/Millennium
Consulting or Advisory Role - AstraZeneca; Takeda/Millennium
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Merck (Inst); Merrimack (Inst); Pfizer (Inst); Takeda/Millennium (Inst)